ABSTRACT. Congenital heart defects (CHDs) are the most common birth defects; genes involved in homocysteine/folate metabolism may play important roles in CHDs. Methionine synthase reductase (MTRR) is one of the key regulatory enzymes involved in the metabolic pathway of homocysteine. We investigated whether two polymorphisms (A66G and C524T) of the MTRR gene are associated with CHDs. A total of 599 children with CHDs and 672 healthy children were included; the polymorphisms were detected by PCR and RFLP analysis. Significant differences in the distributions of A66G and C524T alleles were observed between CHD cases and controls, and slightly increased risks of CHD were associated with 66GG and 524CT genotypes (odds ratios = 1.545 and 1.419, respectively). The genotype frequencies of 524CT in the VSD subgroup, 66GG and 524CT in the PDA subgroup were significantly different from those of controls. In addition, the combined 66AA/524CT, 66AG/524CT and 66GG/524CT in CHDs had odds ratios = 1.589, 1.422 and 1.934, respectively. Increased risks were also observed in 66AA/524CT and 66GG/524CT for ASD, 66AG/524CT for VSD, as well as 66GG/524CT for PDA. In conclusion, MTRR A66G and C524T polymorphisms are associated with increased risk of CHDs.
INTRODUCTION
Congenital heart defects (CHDs), which include the defects of the heart and its major blood vessels, are the most common birth defects and the leading cause of death from birth defects. CHDs occur in approximately 1% of live births, with a much higher percentage in those aborted spontaneously or stillborn (Hoffman and Kaplan, 2002) . Every year, approximately 140-160 thousand children in China are born with CHDs. CHDs are mainly the result of incomplete development of the heart during the first six weeks of pregnancy (Botto et al., 2004) . However, the pathogenesis of CHDs is not fully understood. Population studies have suggested that CHDs are associated with a genetic syndrome (e.g., Down syndrome) or they can be of multifactorial origin, involving genetic and environmental factors (Tennstedt et al., 1999; Botto and Correa, 2003) .
Several population-based studies and experiments with animal models have shown that periconceptional multivitamin/folic acid supplementation has a strong protective effect during early stages of embryo development, resulting in a significant reduction in the occurrence of developmental defects, including neural tube defects, CHDs, limb defects, and facial-clefting (Itikala et al, 2001; Botto et al., , 2004 Czeizel et al., 2004) . Women who take 4 mg folic acid daily from the time of their periconceptional examination until the end of the first trimester of pregnancy have a 40-80% reduced risk of having a baby with neural tube defects (Czeizel and Dudás, 1992; Berry et al., 1999; Huhta et al., 2006) . Several large-scale population-based case-control studies have shown that at least one in four heart defects could be prevented by periconceptional use of multivitamin supplements (Botto et al., 1996 (Botto et al., , 2000 Czeizel, 1998) . In addition, epidemiological evidence has revealed that elevated plasma homocysteine levels (hyperhomocysteinemia) confer an increased risk of congenital defects (Rosenquist et al., 1996; Verkleij-Hagoort et al., 2006) . Low or inadequate intakes of folic acid are involved in the disruption of methionine metabolism, because methytetrahydrofolate, the primary form of folate in the circulation, acts as the carbon donor for homocysteine remethylation to yield methionine and tetrahydrofolate (Elmore et al., 2007) . Therefore, genes that participate in homocysteine/folate metabolism are attractive candidates for investigation of the mechanisms underlying the protective role of folic acid in CHDs (Fredriksen et al., 2007) .
Methionine synthase reductase (MTRR) is one of the key regulatory enzymes involved in the homocysteine metabolic pathway. During methionine synthase (MTR)-catalyzed remethylation, the methyl group of 5-methyltetrahydrofolate is transferred to homocysteine, and Genetics and Molecular Research 10 (4): 2597 -2605 (2011 Polymorphisms of the MTRR gene and CHDs in this cobalamin-dependent reaction, cofactor cob(I)alamin is oxidized to cob(II)alamin, which inactivates MTR. By catalyzing the reductive methylation of cob(II)alamin, MTRR restores MTR activity (Figure 1 ) (Olteanu and Banerjee, 2001; Silaste et al., 2001; Gellekink et al., 2005) . Since MTRR plays a crucial role in maintaining the activity state of MTR, nonsynonymous genetic variations within the MTRR gene may confer susceptible or protective effects against CHDs (Swanson et al., 2001; Elmore et al., 2007; Deng et al., 2008) . The MTRR gene is located on chromosome 5 at 5p15.3-p15.2 (Leclerc et al., 1999) . A common variant has been identified within the flavin mononucleotide-binding domain of the MTRR gene, the A66G polymorphism (rs1801394), which results in an isoleucine-to-methionine (I22M) substitution and appears to interact less effectively with methionine synthase (Olteanu and Banerjee, 2001) . Another polymorphism C524T (rs1532268) leads to an amino acid change from serine to leucine (S175L). To our knowledge, few studies have been published concerning MTRR polymorphisms in relation to CHDs in the Chinese Han population. We investigated whether the two polymorphisms of the MTRR gene are associated with CHDs.
SUBJECTS AND METHODS

Patients and controls
A total 599 children (260 males and 339 females) with CHDs were included in this study from the Department of Pediatric Cardiology, West China Second University Hospital in Chengdu, Sichuan Province, China. All patients were diagnosed based on echocardiography and cardiac catheterization (Table 1) ; 672 healthy subjects (317 males and 355 females) were recruited from the same hospital as the control group via health screening. Folate levels were not measured. Exclusion criteria were race other than Han, CHD in association with aneuploidies and as a part of genetic syndromes, maternal intake of potentially teratogenic pharmaceuticals as well as maternal exposure in an environment, which may cause abnormal embryo development (including smoking, alcohol, toxins, and radiation). All the participants were of the same ethnic origin and this study was approved by the Institutional Ethics Committee of West China Second University Hospital, Chengdu. Table 1 . Classification of the congenital heart disease groups.
Polymorphism detection
Peripheral blood samples were collected from cases and controls in 1-mL EDTA vacutainer tubes, and genomic DNA was extracted using standard salt fractionation and stored at -80°C. Information on the SNPs of the MTRR gene was derived from the SNP database (dbSNP) established by the National Center for Biotechnology Information (http://www.ncbi. nlm.nih.gov/SNP/). Polymorphisms of the MTRR gene were detected by PCR and RFLP analysis (Table 2) .
5'-AAACGGTAAACGGTAAAATCCACTGTAACGGC-3' A allele: 25, 126 bp A/G G allele: 151 bp Table 2 . Details of the PCR-RFLP method to determine each SNP of the MTRR gene.
The PCR was carried out in a volume of 25 µL, containing 100 pmol forward and reverse specific primers, 1.5 U Taq DNA polymerase, 200 µM dNTP, 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 and 3 µL genomic DNA templates. PCR amplification conditions were as follows: after an initial denaturation step of 5 min at 95°C, 35 cycles (denaturation at 95°C for 30 s, annealing for 30 s at 59.3°C, and an extension step at 72°C for 30 s), followed by a final extension for 10 min at 72°C. Restriction enzyme digestion was performed, using specific XhoI and NedI restriction enzymes (New England Biolabs, Beverly, MA, USA), and the digested PCR product was separated by electrophoresis on a 2.5-3% agarose gel. To assure accuracy of the PCR-RFLP results, each sample was analyzed twice. In order to verify the genotypes by PCR-RFLP, the purified PCR products of random samples selected were sequenced directly (Figure 2 ) using the AB Sequence Detection System 7500 v1.4 software package (Applied Biosystems). 
Statistical analysis: case-control study
Genotype and allele frequency distributions of two SNPs in the MTRR gene were compared between CHD cases and controls, using the chi-square test. The odds ratios (OR) were calculated for relative risk along with the 95% confidence intervals (95%CI). All analyses were performed using SPSS for Windows, version 16.0. P values were two-tailed, and were considered to be significant at 0.05.
RESULTS
A66G and C524T allele frequencies
The distribution of the MTRR A66G and C524T alleles in CHD cases and controls was compatible with Hardy-Weinberg equilibrium (Table 3) . A significant difference was observed between CHD cases and controls for A66G. The frequency of the 524T allele was significantly higher in CHD cases than in controls.
W. Zeng et al. Table 4 shows the distributions of MTRR genotypes. There were significant differences in the genotype frequencies of 66GG and 524CT for CHD cases compared with controls.
A66G and C524T genotype frequencies
The prevalence of MTRR A66G and C524T combined genotypes in CHD cases and controls were also investigated (Table 4) . When compared with controls, significant differences were observed in the combined genotype distributions of the three genotypes, 66AA/524CT, 66AG/524CT and 66GG/524CT ( Data are reported as percent with number in parentheses. OR = odds ratio; 95%CI = 95% confidence interval. Data are reported as percent with number in parentheses. OR = odds ratio; 95%CI = 95% confidence interval. 
Subgroup analysis
The MTRR A66G and C524T genotype distributions of CHD subgroups were compared with controls (Table 5 ). The genotype frequencies of 524CT in the ventricular septal defect (VSD) subgroup, 66GG and 524CT in the patent ductus arteriosus (PDA) subgroup were significantly different from those of controls.
There were significant differences in the distributions of three combined genotypes (66AA/524CT, 66AG/524CT and 66GG/524CT) between CHDs and controls. To further identify the association between these three combined genotypes and CHD risk, we explored their distributions in the CHD subgroups. The frequencies of 66AA/524CT and 66GG/524CT genotypes in patients with atrial septal defect (ASD) were significant higher than controls. We also found that the frequency of 66AG/524CT genotype in patients with VSD and 66GG/524CT genotype in patients with PDA were significant higher than controls.
DISCUSSION
Single nucleotide polymorphisms are very helpful for finding genes that contribute to diseases (Brookes, 1999) . Some SNP alleles are the actual DNA sequence variants that cause differences in gene function or regulation that directly contribute to disease processes (Brookes, 1999; Lai, 2001) . Most SNP alleles, however, probably contribute little to disease. They are useful as genetic markers that can be used to find the functional SNPs because of associations between the marker SNPs and the functional SNPs.
Since MTRR is essential to maintain MTR function, it is a central regulatory enzyme in the metabolic pathway of homocysteine/folate. Malfunctioning of this enzyme may be associated with hyperhomocysteinemia. Hyperhomocysteinemia has been regarded as a modifiable risk factor for heart and vascular disease, because it is one of the causes of endothelial damage (Kapusta et al., 1999; Tierney et al., 2004; Verkleij-Hagoort et al., 2006) .
In this case-control study, we looked for a possible association between the A66G and C524T polymorphisms of the MTRR gene and the development of CHDs. We calculated the ORs (see Tables 3, 4 and 6) and found that moderately higher risks of CHD were associated with 66GG and 524CT genotypes. We noted that even the 524T allele in CHD cases had a higher frequency than in controls; there were no significant differences in 524TT frequencies between the two groups. Possibly, the 524TT genotype was present at a low frequency in the population, and due to the limited sample size in our study, we did not detect differences between the two groups.
Considering the interaction of the two genotypes, we further explored the combined genotype frequencies of A66G and C524T of the MTRR gene. The combined 66AA/524CT, 66AG/524CT and 66GG/524CT gave significant ORs. The combined 66AA/524CT and 66AG/524CT genotypes of the MTRR gene may be risk factors for CHDs.
In order to find out whether the A66G and C524T polymorphisms of the MTRR gene have different effects on the most common types of CHD, we compared the frequencies in the four subgroups of CHD cases with controls. Many of the ORs were above 1, but only four of them reached significance (Tables 5 and 6 ). The patients with the combined genotypes 66AA/524CT and 66GG/524CT had higher risks of ASD (2.2-and 3.22-fold, respectively). In addition, the 66AG/524CT combined genotype was associated with a 1.6-fold higher risk of VSD, while the 66GG/524CT combined genotype was associated with a 2.5-fold increased risk of PDA, compared with controls. Although some previous researchers reported that the two polymorphisms (A66G and C524T) of the MTRR gene are not associated with an increased risk of CHDs (van Beynum et al., 2006; Fredriksen et al., 2007; Verkleij-Hagoort et al., 2008; Shaw et al., 2009 ), we found a modest association between the A66G and C524T alleles of the MTRR gene and CHDs in the Chinese Han population. These differences between reports might be due to ethnic heterogeneity. However, as information concerning t-Hcy levels and the maternal genotypes of MTRR A66G and C524T polymorphisms is not available for all subjects, we could not further clarify the mechanism underlying the relationship between the MTRR A66G and C524T polymorphisms and CHD.
In conclusion, MTRR A66G and C524T polymorphisms are associated with increased risks of suffering CHDs. To further elucidate the relationship between MTRR A66G and C524T polymorphisms and CHDs, other risk factors, such as t-Hcy levels, enzyme activity, parental genotypes, and vitamin complex intakes should be investigated. For subgroup abbreviations, see Table 1 . Table 6 . Calculated odds ratios (OR) with 95%CI (confidence intervals; in parentheses) of the MTRR polymorphisms in congenital heart disease subgroups.
